ELI LILLY AND COMPANY Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount
ELI LILLY AND COMPANY (LLY) reported Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount of $299.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsForeign · last filed 2023-02-22
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2022 was $299.50M, a 33.07% decline from fiscal 2021.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2021 was $447.50M, a 50.57% increase from fiscal 2020.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2020 was $297.20M, a 22.81% increase from fiscal 2019.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2019 was $242.00M, a 61.41% decline from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 12 month as first filed |
|---|---|---|
| 2022-12-31 | $299.50M 10-K · filed 2023-02-22 | |
| 2021-12-31 | $447.50M 10-K · filed 2023-02-22 | $458.20M 10-K · filed 2022-02-23 |
| 2020-12-31 | $297.20M 10-K · filed 2023-02-22 | $297.10M 10-K · filed 2021-02-17 |
| 2019-12-31 | $242.00M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $627.10M 10-K · filed 2021-02-17 | $629.70M 10-K · filed 2019-02-19 |
| 2017-12-31 | $480.80M 10-K · filed 2020-02-19 | $428.90M 10-K · filed 2018-02-20 |
| 2016-12-31 | $357.20M 8-K · filed 2019-10-24 | $313.70M 10-K · filed 2017-02-21 |
| 2015-12-31 | $565.20M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $344.80M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $778.30M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |